@TomPrt

#MD #pulmonologist #lungcancer

 Lyon, France
Joined February 2012
  • Tweets4.6K
  • Following757
  • Followers375
22Media
Thomas Pierret 🫁 retweeted
Clive Peedell@cpeedell16h
My *practice changing* take home messages from #ESMO26 to NHS lung cancer teams: Immediate change: 1. PERSEE. Bottom line - Chemo still alive for PDL1 >50%. Median OS 50.2m Vs 29.9m. Works just as well for 90-100% group too Fitter, younger should get Chemo even PDL1 100% #ESMO26
4
7
31
4,413
Thomas Pierret 🫁 retweeted
Stephen V Liu, MD
@StephenVLiu22h
#ESMO26 Dr. Jarushka Naidoo @DrJNaidoo with a fantastic discussion on de-escalation trials in oncology. A call out on why de-escalation studies are important and their limitations. And for MOIO in particular - lessons on trial design, non-inferiority, and pragmatism. A must-listen to all involved in trial design. #ESMOAmbassadors
2
20
1
40
2,765
Thomas Pierret 🫁 retweeted
Stephen V Liu, MD
@StephenVLiu23h
#ESMO26 One of my favorite discussant. Dr @JordiRemon discusses early stage immunotherapy abstracts. Many options in the neoadjuvant and perioperative space, summarized beautifully. What is the value of adjuvant immunotherapy? Is receipt of adjuvant therapy a surrogate for fitness? #ESMOAmbassadors
2
21
71
2,855
Thomas Pierret 🫁 retweeted
Giannis Mountzios@g_mountzios23h
#ESMO26 Does Tarlatamab provide long term benefit to responding patients? ✅The answer is Yes! ➡️Extended F-UP of the Dellphi-304 trial shows that after 22m of F-UP Landmark 2-year OS was 30% vs 15% and sustained disease control in 24% of patients at > 52 weeks ❓We need to investigate the characteristics of those patients to understand how we can improve the outcomes of the 70% of patients who do not make it to two years @myESMO #ESMOAmbassadors
1
16
36
1,738
Thomas Pierret 🫁 retweeted
Annals of Oncology@Annals_OncologyOct 26
📢 #ESMO26 concomitant paper: Extended follow-up of #tarlatamab in patients with small-cell lung cancer after platinum-based chemo in the phase 3 DeLLphi-304 study. 🔗shorturl.at/QFAwC @JulienMazieres @pedrofrocha @UniklinikEssen @medizinischefakultaet @g_mountzios
7
2
9
1,750
Thomas Pierret 🫁 retweeted
Hidehito HORINOUCHI
@HHorinouchiOct 26
🔥DeLLphi-304: Extended follow-up of tarlatamab vs chemo in 2L SCLC 🆙 @Annals_Oncology #ESMO26 🎙 @charlesrudin 🎯Durable OS Benefit at 23-Mo Median Follow-Up 🎯mOS 13.6 vs 8.4mo (HR 0.62); 18-Mo OS 42% vs 24% 🎯Grade≥3 TRAEs 28% vs 63% ☑️NCT05740566 @OncoAlert @Larvol @myESMO @IASLC annalsofoncology.org/article…

Extended follow-up of tarlatamab in patients with small-cell lung cancer after platinum-based...

In the DeLLphi-304 trial, at a median follow-up of <12 months, tarlatamab significantly improved overall survival (OS), progression-free survival (PFS), and patient-reported outcomes (PROs), and...

annalsofoncology.org
Hidehito HORINOUCHI
@HHorinouchiOct 26
🆙#ESMO26 Proffered Paper: #LCSM Non-Mets 🔥DeLLphi-304: Tarlatamab in Previously Treated SCLC: Extended Follow-Up of Overall Survival From the Phase 3 Trial 🎙️ @charlesrudin 🔢3808O 🎯Durable OS Benefit at 23-Mo Median Follow-Up 🎯mOS 13.6 vs 8.4mo (HR 0.62); 18-Mo OS 42% vs 24% 🎯Grade≥3 TRAEs 28% vs 63% ☑️NCT05740566 🔗 cslide.ctimeetingtech.com/es… @OncoAlert @Larvol @myESMO @IASLC
8
9
655
Thomas Pierret 🫁 retweeted
Hidehito HORINOUCHI
@HHorinouchiOct 26
🆙#ESMO26 Proffered Paper: #LCSM Non-Mets 🔥DeLLphi-304: Tarlatamab in Previously Treated SCLC: Extended Follow-Up of Overall Survival From the Phase 3 Trial 🎙️ @charlesrudin 🔢3808O 🎯Durable OS Benefit at 23-Mo Median Follow-Up 🎯mOS 13.6 vs 8.4mo (HR 0.62); 18-Mo OS 42% vs 24% 🎯Grade≥3 TRAEs 28% vs 63% ☑️NCT05740566 🔗 cslide.ctimeetingtech.com/es… @OncoAlert @Larvol @myESMO @IASLC
Hidehito HORINOUCHI
@HHorinouchiOct 21
🆙#ESMO26 Proffered Paper: #LCSM Non-Mets 🔥DeLLphi-304: Tarlatamab in Previously Treated SCLC: Extended Follow-Up of Overall Survival From the Phase 3 Trial 🎙️ @charlesrudin 🔢3808O 🎯Durable OS Benefit at 23-Mo Median Follow-Up 🎯mOS 13.6 vs 8.4mo (HR 0.62); 18-Mo OS 42% vs 24% 🎯Grade≥3 TRAEs 28% vs 63% ☑️NCT05740566 🔗 cslide.ctimeetingtech.com/es… @OncoAlert @Larvol @myESMO @IASLC
4
6
1
14
1,682
Thomas Pierret 🫁 retweeted
Stephen V Liu, MD
@StephenVLiuOct 26
#ESMO26 Dr. @RobertoFerrara_ explains next-generation immune toxicities seen with next-generation immunotherapies. Rational design of SCORPION vs CRAB antibodies is a good example of intentional design to address toxicities. Very helpful overview. #ESMOAmbassadors
9
19
1,062
Thomas Pierret 🫁 retweeted
Dr. Antonio Calles 🫁🚭
@Tony_CallesOct 26
Savo + Osi >>> Osi In 1L stage IV, EGFRmut: Better PFS and remarkable 44.5 OS for a poor prognosis population, with the cost of more MET-related side effects. High attrition to find MET-IHC3+. Wondering how this data compares to this subset of patients in the MARIPOSA trial. #ESMO26 #LCSM
1
4
14
622
Thomas Pierret 🫁 retweeted
Dr Amol Akhade
@SuyogCancerOct 26
ESMO 2026 | A cautionary tale for immunotherapy de-escalation! MOIO Trial (LBA10) – Phase III non-inferiority trial testing 3-monthly immunotherapy vs standard dosing in responding patients with advanced/metastatic cancer. 📊 Key results (N=308): • Median PFS: 21.9 vs 25 months (reduced vs standard; HR 1.35) • Risk of death: HR 2.0 (95% CI 1.1–3.9; p=0.0143) ⚠️ • PFS HR in urothelial cancer: 2.9 • Grade 3–4 immune-related AEs: 9.5% vs 10.5% ❌ Non-inferiority NOT demonstrated. ❌ No meaningful safety advantage. ⚠️ Signal of inferior survival with reduced-frequency IO. 💡 Take-home: Less frequent immunotherapy is not necessarily equally effective! Important: These are interim results with relatively small numbers and heterogeneous tumour types. #ESMO26 #MOIO #Immunotherapy #Oncology @OncoAlert @myESMO
2
22
2
59
10,644
Thomas Pierret 🫁 retweeted
Patrick Forde@FordePatrickOct 25
Replying to @Alfdoc2
Pembro monotherapy still has a role in selected pts (borderline ECOG PS or where a pt does not want to do chemo) but the control arm did not underperform. The final median PFS for Pembro mono in KN024 was only 3 weeks less than the control arm performance in PERSEE was it not?
1
2
9
346
Thomas Pierret 🫁 retweeted
Stephen V Liu, MD
@StephenVLiuOct 25
Brilliant discussion from Dr. @BenjaminBesseMD at #ESMO26 on the Krascendo 1 study of divarasib vs sotorasib/adagrasib. Rightly points out lack of crossover in a study with a PFS endpoint as unjust. Excellent points all around. #ESMOAmbassadors
1
21
1
73
3,540
Thomas Pierret 🫁 retweeted
IFCT lung@IFCTlungOct 25
Congrats to Prof. @ToffartC on his very clear presentation of the results from Phase 2 part of the IFCT-2103 DIAL trial (de-escalation of pembro at 6 months). There was no detrimental effect (OS) at 18 and 24 months (93 first randomized pts).. #ESMO26
2
7
13
411
Thomas Pierret 🫁 retweeted
Dr. Antonio Calles 🫁🚭
@Tony_CallesOct 25
Replying to @GautschiOliver
No information by molecular subtypes (eg KRAS mut) or elderly patients where combination may be not necessary or even detrimental because of side effects.
1
40
Thomas Pierret 🫁 retweeted
Noemi Reguart@NReguartOct 25
Impressive results Academic III PERSEE #ESMO26 @Annals_Oncology First positive random trial adding chemo to pembro in PD-L1 ≥50% NSCLC: 🔹 PFS: 16.1 vs 6.9 mo HR 0.56 🔹 OS: 50.2 vs 29.9 mo HR 0.77, NS 🔹 G≥3 TRAEs: 54% vs 19% Outstanding discussion Prof. Levy @benlevylungdoc.
12
24
965
Thomas Pierret 🫁 retweeted
Julien Mazieres@JulienMazieresOct 25
‼️ In first line treatment of advanced PD-L1 ≥50% NSCLC, PERSEE demonstrates a significant improvement of PFS with pembro-CT compared to pembro monotherapy regardless of PDL1 level of (over)expression. Practise changing trial. @myESMO @OncoAlert #ESMO26 👏👏👏 @decroisette
18
49
2,982
Thomas Pierret 🫁 retweeted
Gerry Hanna
@gerryhannaOct 25
Randomised phase 3 Persée study presented at #ESMO26 this morning ➡️ chemotherapy and Pembrolizumab improved OS when compared with Pembro alone in patients with local advanced NSCLC with PD-L1 ≥50%
11
16
1,111
Thomas Pierret 🫁 retweeted
Stephen V Liu, MD
@StephenVLiuOct 25
Off the rousing #ESMO26 oral presentation from Dr. @decroisette, the phase III PERSEE trial with simultaneous publication @Annals_Oncology. Combination of chemotherapy + pembrolizumab superior to pembro in PDL1 high NSCLC: PFS 16.1 vs 6.9m, HR 0.56! annalsofoncology.org/article…

Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC...

Pembrolizumab, alone or combined with platinum-based chemotherapy, is a standard first-line treatment for patients with metastatic non-small-cell lung cancer (NSCLC) without actionable oncogenic...

annalsofoncology.org
2
23
3
67
6,062
Thomas Pierret 🫁 retweeted
Hidehito HORINOUCHI
@HHorinouchiOct 25
🆙#ESMO26 Proffered Paper I: #LCSM Mets 🔥OptiTROP-Lung04: Final OS Analysis of Sacituzumab Tirumotecan (Sac-TMT) Versus Platinum-Based Chemotherapy in EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) After Progression on EGFR-TKI: Phase III Study 🎙️Dr. Wenfeng Fang 🔢LBA67 🎯Sustained OS Benefit at 32.3-Mo Follow-Up 🎯Median OS 25.9 vs 17.4mo (HR 0.69; n=376) 🎯24-Mo OS 54.1% vs 37.2% ☑️NCT05870319 🔗 cslide.ctimeetingtech.com/es… @OncoAlert @Larvol @myESMO @IASLC @EGFRResisters
Hidehito HORINOUCHI
@HHorinouchiSep 23
🆙 #ESMO26 Proffered Paper I: #LCSM Mets 🔥OptiTROP-Lung04: Final OS Analysis of Sacituzumab Tirumotecan (Sac-TMT) Versus Platinum-Based Chemotherapy in EGFR-Mutated NSCLC After Progression on EGFR-TKI 🎙️Dr. Li Zhang 🔢LBA67 ☑️NCT05870319 🔗 cslide.ctimeetingtech.com/es… @OncoAlert @Larvol @myESMO @IASLC @EGFRResisters
6
1
8
2,022
Thomas Pierret 🫁 retweeted
Yakup Ergün
@dr_yakupergunOct 25
#ESMO26 | SAFFRON | Presidential Session-2 In EGFR-mutant, MET-overexpressed/amplified advanced NSCLC after osimertinib: Osimertinib + savolitinib vs platinum-pemetrexed: 🔹 PFS: 7.6 vs 5.4 mo (HR 0.55) 🔹 OS: 17.8 vs 12.9 mo(HR 0.68)
2
1
3
1,329
Load more